Boston Scientific + Shanghai Lingang Special Area
Boston Scientific
Marlborough, Massachusetts · 1 relationship
Active relationship
Wholly-Owned · 2024–present
Shanghai Lingang Special Area
Shanghai, Shanghai · 2 relationships
Analysis
Boston Scientific opened its first manufacturing base in China on October 15, 2024, at the Lin-gang Life Science & Tech Park in Shanghai's Lin-gang Special Area. The project followed a 2023 launch agreement and formed part of the company's shift from an import-led presence toward local manufacturing and product localization. [1] [2]
The facility includes laboratories, production workshops, warehouses and cleanrooms built to Chinese and international standards. Lin-gang authorities describe digital production and management systems that provide monitoring and traceability from raw materials to finished devices, with an initial focus on medical consumables and equipment. [1]
The local-government role extends beyond providing industrial space. Lin-gang publicized policies intended to accelerate review, registration and market launch for products made at the site, while Boston Scientific brought global factory methods and regulated-device manufacturing processes; this combination is meant to shorten the supply path to Chinese hospitals. [1] [3]
In March 2026, China's National Medical Products Administration approved the OptiCross HD intravascular-ultrasound catheter for local manufacture at Lin-gang, the first domestically approved device designated for production at the base. Shanghai reporting also identified OptiCross products among the site's first local production programs, showing the partnership moving from construction into regulated commercial output. [2] [4]
Participants
Continue through either entity
Marlborough, Massachusetts · 1 record in this database
Boston Scientific Corporation is a global developer, manufacturer and marketer of medical devices for interventional medical specialties. The company says it has been a medical-technology leader for more than 45 years and has advanced less-invasive medicine by giving clinicians alternatives to surgery and other procedures that can be traumatic to the body. [1]
The business grew from the catheter-based medical-device company Medi-Tech; Boston Scientific identifies John Abele and Pete Nicholas as co-founders, and Nicholas's company biography describes the startup as having been built with fewer than 50 employees and early capital of a $500,000 loan plus $300,000 from partners. [2]
For 2025, Boston Scientific's products were organized into two reportable segments and five core businesses: Endoscopy, Urology and Neuromodulation in MedSurg, and Cardiology and Peripheral Interventions in Cardiovascular. The company develops endoscopic devices for gastrointestinal conditions, urological technologies for kidney stones, benign prostatic hyperplasia, prostate cancer and pelvic-health disorders, and implantable neuromodulation technologies for chronic pain and neurological conditions. [1] [3]
Its cardiovascular and electrophysiology portfolio includes technologies for heart and vascular conditions, cardiac-rhythm disorders and stroke-risk reduction, including the WATCHMAN left-atrial-appendage closure device. Boston Scientific reported $20.1 billion in fiscal-2025 sales, and its stated strategy is to strengthen category leadership, expand into high-growth adjacencies and extend global access to interventional technologies. [3] [4]
Shanghai, Shanghai · 2 records in this database
Lin-gang Special Area is a geographic and administrative area within the China (Shanghai) Pilot Free Trade Zone, not a single operating company. Its official overview places it south of the Dazhi River and south of Pudong International Airport; initial development covers Nanhui New Town, Lin-gang Equipment Industrial Zone, Xiaoyangshan Island and the southern part of Pudong airport. The area sits between Pudong airport and Yangshan International Port and is administered through a dedicated Lin-gang administration. [1]
Shanghai’s 2025 review says Lin-gang was established in 2019 and had introduced more than 679 key projects in frontier-technology industries, attracting over RMB730 billion in investment. The same official account reports average annual growth of industrial output above designated size of 28.4 percent, while integrated circuits, civil aviation, biopharmaceuticals and artificial intelligence recorded a combined average annual growth rate of 38.3 percent; the IC sector’s six-year average growth exceeded 50 percent. [2]
The area’s policy role is expressed through institutional experiments as well as industrial development. An official 2025 account reports 166 institutional-innovation cases, including 79 national firsts, and says a Yangshan Free Trade Zone customs policy cut overall clearance time from two days to two hours and reduced costs by 50 percent. Lin-gang’s 2025 business-environment agenda also targeted cross-border and offshore finance, trade, data, healthcare and shipping services. These measures frame Lin-gang as a coastal testbed linking trade facilitation, technology commercialization and advanced manufacturing. [3] [4]